Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Clinical trial NCT02902042 · COMPLETED
Trial details
- NCT number
- NCT02902042
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-24
- Primary completion
- 2020-11-30
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.